A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer

•EP-100 with weekly paclitaxel was shown to be safe and well tolerated.•Patients in the combination arm received extended treatment beyond 6 cycles.•Liver metastasis demonstrated greater benefit from combination as compared to paclitaxel in a posthoc analysis.•There was no difference in response rate with the addition of EP-100 to paclitaxel in the overall population.